Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 On the architecture of translational research designed to control chronic lymphocytic leukemia.

Literature DB >> 30504285

On the architecture of translational research designed to control chronic lymphocytic leukemia.

Abstract

Chronic lymphocytic leukemia (CLL) has been 1 of the most dynamic fields of clinical research over the last 2 decades. Important advances in understanding the biology of CLL have led to the development of new prognostic and diagnostic tools. Concurrently, several recently approved new agents hold the potential to fundamentally change the management of this leukemia and have started to improve clinical outcomes for patients. This conceptual review summarizes the major recent insights regarding the biology of CLL, the technological advances that have allowed refinement of the prognostication of the clinical course, and the new therapeutic strategies that are currently under investigation to further ameliorate the outcome for patients with CLL.

Entities: Disease Species

Mesh：

Year: 2018 PMID： 30504285 PMCID： PMC6245981 DOI： 10.1182/asheducation-2018.1.1

Source DB: PubMed Journal: Hematology Am Soc Hematol Educ Program ISSN： 1520-4383

87 in total

1. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Authors: J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn
Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544

2. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.

Authors: G Dighiero; K Maloum; B Desablens; B Cazin; M Navarro; R Leblay; M Leporrier; J Jaubert; G Lepeu; B Dreyfus; J L Binet; P Travade
Journal: N Engl J Med Date: 1998-05-21 Impact factor: 91.245

3. Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.

Authors: Massimo Gentile; Tait D Shanafelt; Davide Rossi; Luca Laurenti; Francesca R Mauro; Stefano Molica; Giovanna Cutrona; Giuseppina Uccello; Melissa Campanelli; Ernesto Vigna; Giovanni Tripepi; Kari G Chaffee; Sameer A Parikh; Sabrina Bossio; Anna Grazia Recchia; Idanna Innocenti; Raffaella Pasquale; Antonino Neri; Manlio Ferrarini; Gianluca Gaidano; Robin Foà; Fortunato Morabito
Journal: Blood Date: 2016-08-22 Impact factor: 22.113

4. Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.

Authors: Massimo Gentile; Tait D Shanafelt; Francesca R Mauro; Luca Laurenti; Davide Rossi; Stefano Molica; Iolanda Vincelli; Giovanna Cutrona; Giuseppina Uccello; Sara Pepe; Ernesto Vigna; Giovanni Tripepi; Kari G Chaffee; Sameer A Parikh; Sabrina Bossio; Anna Grazia Recchia; Idanna Innocenti; Raffaella Pasquale; Antonino Neri; Manlio Ferrarini; Gianluca Gaidano; Robin Foà; Fortunato Morabito
Journal: Am J Hematol Date: 2017-11-23 Impact factor: 10.047

Review 5. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

Authors: Adrian Wiestner
Journal: Hematology Am Soc Hematol Educ Program Date: 2012

6. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

Authors: William G Wierda; Susan O'Brien; Xuemei Wang; Stefan Faderl; Alessandra Ferrajoli; Kim-Anh Do; Jorge Cortes; Deborah Thomas; Guillermo Garcia-Manero; Charles Koller; Miloslav Beran; Francis Giles; Farhad Ravandi; Susan Lerner; Hagop Kantarjian; Michael Keating
Journal: Blood Date: 2007-02-13 Impact factor: 22.113

7. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Authors: Ulf Klein; Marie Lia; Marta Crespo; Rachael Siegel; Qiong Shen; Tongwei Mo; Alberto Ambesi-Impiombato; Andrea Califano; Anna Migliazza; Govind Bhagat; Riccardo Dalla-Favera
Journal: Cancer Cell Date: 2010-01-07 Impact factor: 31.743

8. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors: Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal: N Engl J Med Date: 2015-12-06 Impact factor: 91.245

9. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.

Authors: Carmen Diana Herling; Marion Klaumünzer; Cristiano Krings Rocha; Janine Altmüller; Holger Thiele; Jasmin Bahlo; Sandra Kluth; Giuliano Crispatzu; Marco Herling; Joanna Schiller; Anja Engelke; Eugen Tausch; Hartmut Döhner; Kirsten Fischer; Valentin Goede; Peter Nürnberg; Hans Christian Reinhardt; Stephan Stilgenbauer; Michael Hallek; Karl-Anton Kreuzer
Journal: Blood Date: 2016-05-25 Impact factor: 22.113

10. BTK^C481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

Authors: Jennifer A Woyach; Amy S Ruppert; Daphne Guinn; Amy Lehman; James S Blachly; Arletta Lozanski; Nyla A Heerema; Weiqiang Zhao; Joshua Coleman; Daniel Jones; Lynne Abruzzo; Amber Gordon; Rose Mantel; Lisa L Smith; Samantha McWhorter; Melanie Davis; Tzyy-Jye Doong; Fan Ny; Margaret Lucas; Weihong Chase; Jeffrey A Jones; Joseph M Flynn; Kami Maddocks; Kerry Rogers; Samantha Jaglowski; Leslie A Andritsos; Farrukh T Awan; Kristie A Blum; Michael R Grever; Gerard Lozanski; Amy J Johnson; John C Byrd
Journal: J Clin Oncol Date: 2017-02-13 Impact factor: 50.717

5 in total

1. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.

Authors: Tiziana Vaisitti; Francesca Arruga; Nicoletta Vitale; Thanh-Trang Lee; Mira Ko; Amy Chadburn; Esteban Braggio; Arianna Di Napoli; Andrea Iannello; John N Allan; Langdon L Miller; Brian J Lannutti; Richard R Furman; Katti A Jessen; Silvia Deaglio
Journal: Blood Date: 2021-06-17 Impact factor: 22.113

Review 2. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?

Authors: Junji Suzumiya; Jun Takizawa
Journal: Int J Hematol Date: 2020-04-06 Impact factor: 2.319

3. Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?

Authors: Antonio Cuneo; Robin Foà
Journal: Mediterr J Hematol Infect Dis Date: 2019-03-01 Impact factor: 2.576

4. A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia.

Authors: Jared A Cohen; Francesca Maria Rossi; Antonella Zucchetto; Riccardo Bomben; Lodovico Terzi-di-Bergamo; Kari G Rabe; Massimo Degan; Agostino Steffan; Jerry Polesel; Enrico Santinelli; Idanna Innocenti; Giovanna Cutrona; Giovanni D'Arena; Gabriele Pozzato; Francesco Zaja; Annalisa Chiarenza; Davide Rossi; Francesco Di Raimondo; Luca Laurenti; Massimo Gentile; Fortunato Morabito; Antonino Neri; Manlio Ferrarini; Christopher D Fegan; Christopher J Pepper; Giovanni Del Poeta; Sameer A Parikh; Neil E Kay; Valter Gattei
Journal: Haematologica Date: 2019-10-03 Impact factor: 9.941

5. SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation

Authors: Federico Pozzo; Tamara Bittolo; Erika Tissino; Filippo Vit; Elena Vendramini; Luca Laurenti; Giovanni D'Arena; Jacopo Olivieri; Gabriele Pozzato; Francesco Zaja; Annalisa Chiarenza; Francesco Di Raimondo; Antonella Zucchetto; Riccardo Bomben; Francesca Maria Rossi; Giovanni Del Poeta; Michele Dal Bo; Valter Gattei
Journal: Haematologica Date: 2021-12-01 Impact factor: 9.941

5 in total